Reading view
Active Adaptation, Not Static Defense: Temporal Dynamics of Preventative Steering in Adversarial Fine-Tuning
JT-SAFE-V2: Safety-by-Design Foundation Model with World-Context Data
DeGRe: Dense-supervised Generative Reranking for Recommendation
Explainable multi-omics modeling for risk stratification in pancreatic ductal adenocarcinoma
Gland Surg. 2026 Apr 30;15(4):91. doi: 10.21037/gs-2025-396. Epub 2026 Mar 27.
ABSTRACT
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies due to a lack of reliable tools for individualized risk stratification. A comprehensive understanding of the multi-omics landscape may uncover clinically applicable biomarkers and inform precision prognostic assessment. This study aims to establish a prognostic model directly from the complete omics landscape and extract biomarkers.
METHODS: We developed prognostic models using multi-omics data from a PDAC proteogenomic cohort comprising 75 deceased tumor samples. An independent cohort of 63 deceased PDAC cases from The Cancer Genome Atlas (TCGA)-pancreatic adenocarcinoma (PAAD) was used for external validation. Logistic regression models with least absolute shrinkage and selection operator (LASSO) regularization were constructed, and SHapley Additive exPlanations (SHAP) were applied to evaluate feature importance and identify signature genes. Model selection was based on the average area under the receiver operating characteristic curve (AUROC) across cross-validation folds. Functional validation was performed in PANC-1 cells by knockdown (KD) or overexpression (OE) of representative microRNA-, RNA-, and proteomics-derived signature genes, followed by Cell Counting Kit-8 (CCK-8) proliferation and Transwell migration assays.
RESULTS: Systematic evaluation of 120 multi-omics combinations identified a top-performing prognostic model integrating RNA, microRNA, proteomics, and mutation features. This model achieved a mean AUROC of 0.92±0.11 and accuracy of 0.87±0.01 on internal validation, and 0.99±0.00 and 0.98±0.01 on the TCGA test set. The sensitivity, specificity, precision, recall and F1 scores on the TCGA test set were 0.98±0.01, 0.97±0.02, 0.98±0.02, 0.98±0.01, 0.98±0.01, respectively. SHAP analysis revealed interpretable and clinically relevant prognostic biomarkers, many of which are implicated in immune signaling, metabolic regulation, and cell cycle control. Importantly, modulation of representative signature genes in PANC-1 cells significantly altered proliferation and migration in directions consistent with model-predicted risk associations.
CONCLUSIONS: Our findings demonstrate that explainable multi-omics machine learning frameworks can identify robust prognostic biomarkers and achieve highly accurate survival prediction in PDAC. Functional validation further supports the biological relevance of these signatures, underscoring their translational potential for personalized risk assessment.
PMID:42164702 | PMC:PMC13184197 | DOI:10.21037/gs-2025-396
Spatial multi-omics defines cancer-associated fibroblasts subtype gradients driving metabolic support and immune remodeling in pancreatic ductal adenocarcinoma
Cancer Lett. 2026 May 16;653:218585. doi: 10.1016/j.canlet.2026.218585. Online ahead of print.
ABSTRACT
Pancreatic ductal adenocarcinoma is characterized by a fibrotic and metabolically active tumor microenvironment where cancer-associated fibroblasts (CAFs) mediate metabolic crosstalk, extracellular matrix (ECM) remodeling, and immune regulation. However, the metabolic and spatial heterogeneity of CAFs remains incompletely understood. We integrated spatial transcriptomics and spatial metabolomics data from PDAC tissues and performed SpatialGlue-based multimodal clustering to define CAF subtypes. To characterize metabolic communication, we developed an optimal transport (OT)-based metabolic inference framework to quantitatively model metabolite association between CAFs and tumor cells. Subtype-specific features were independently validated using an independent spatial metabolomics cohort and multiplex immunofluorescence (mIHC) staining. Furthermore, these features were correlated with clinical outcomes via TCGA-PAAD deconvolution. Spatial multi-omics integration identified three robust CAF subtypes with distinct signatures. OT analysis revealed differential metabolic interactions: CAF_C0 mediated amino acid/peptide transfer, CAF_C1 was the primary source of lipids, while CAF_C2 exhibited limited metabolic association but stronger immune and ECM signaling activity. Deconvolution confirmed that CAF composition was strongly associated with prognosis; CAF_C2 enrichment predicted poorer survival and gemcitabine resistance, whereas a higher CAF_C0/CAF_C1 balance correlated with improved outcomes. By combining spatial multi-omics with OT-based modeling, this study delineates metabolically and spatially distinct CAF states with clinical relevance. Our findings suggest CAFs act as both metabolic donors and immune-ECM regulators, providing new insights into stromal reprogramming and potential subtype-specific therapeutic targets in PDAC.
PMID:42144098 | DOI:10.1016/j.canlet.2026.218585
WNT7A correlates with immunosuppression and predicts adverse prognosis in lung adenocarcinoma: Potential implication of the NF-kappaB/CCL2 Axis
Cytokine. 2026 Apr 6;202:157144. doi: 10.1016/j.cyto.2026.157144. Online ahead of print.
ABSTRACT
BACKGROUND: The remodeling of the tumor immune microenvironment (TME) is a pivotal determinant of therapeutic efficacy and clinical outcome in Lung Adenocarcinoma (LUAD). While WNT signaling is a known oncogenic driver, the specific immunomodulatory role of WNT7A and its potential crosstalk with inflammatory pathways in LUAD remain to be fully elucidated. We sought to define the prognostic value of WNT7A and explore the molecular mechanisms by which it may foster an immunosuppressive TME.
METHODS: We performed a multi-omics analysis utilizing the TCGA-LUAD cohort (N = 508) and validated findings in an independent external cohort (GSE30219, N = 293). The prognostic significance of WNT7A was evaluated using Kaplan-Meier and multivariate Cox regression analyses. TME composition was dissected via ssGSEA, focusing on myeloid-derived suppressor cell (MDSC) infiltration. Mechanistic pathways were identified using Gene Set Enrichment Analysis (GSEA) and gene co-expression networks.
RESULTS: High WNT7A expression was identified as a significant predictor of poor Overall Survival (OS) in the TCGA cohort (P < 0.05) and validated in the external cohort (P < 0.05). Multivariate analysis confirmed WNT7A as an independent prognostic risk factor (HR = 1.085, P = 0.036). Immunologically, WNT7A expression was positively correlated with MDSC infiltration (R = 0.43, P < 0.001), suggesting a shift towards an immune-tolerant phenotype. Mechanistically, GSEA revealed a robust activation of inflammatory signaling in the high-WNT7A group. Specifically, the TNFA Signaling via NF-κB pathway was significantly enriched(NES = 2.52, P < 0.001). Consistent with this pathway activation, WNT7A showed a statistically significant positive correlation with CCL2 (P < 0.001), a critical chemokine for MDSC recruitment, implicating the NF-κB/CCL2 axis in this process.
CONCLUSION: WNT7A serves as a prognostic biomarker linked to immune evasion in LUAD, potentially by modulating the NF-κB/CCL2/MDSC axis. This study identifies WNT7A as a potential therapeutic target to remodel the immune microenvironment, providing a rationale for future investigations into WNT-targeted strategies to improve immunotherapy efficacy.
PMID:41946008 | DOI:10.1016/j.cyto.2026.157144
WNT7A correlates with immunosuppression and predicts adverse prognosis in lung adenocarcinoma: Potential implication of the NF-kappaB/CCL2 Axis
Cytokine. 2026 Apr 6;202:157144. doi: 10.1016/j.cyto.2026.157144. Online ahead of print.
ABSTRACT
BACKGROUND: The remodeling of the tumor immune microenvironment (TME) is a pivotal determinant of therapeutic efficacy and clinical outcome in Lung Adenocarcinoma (LUAD). While WNT signaling is a known oncogenic driver, the specific immunomodulatory role of WNT7A and its potential crosstalk with inflammatory pathways in LUAD remain to be fully elucidated. We sought to define the prognostic value of WNT7A and explore the molecular mechanisms by which it may foster an immunosuppressive TME.
METHODS: We performed a multi-omics analysis utilizing the TCGA-LUAD cohort (N = 508) and validated findings in an independent external cohort (GSE30219, N = 293). The prognostic significance of WNT7A was evaluated using Kaplan-Meier and multivariate Cox regression analyses. TME composition was dissected via ssGSEA, focusing on myeloid-derived suppressor cell (MDSC) infiltration. Mechanistic pathways were identified using Gene Set Enrichment Analysis (GSEA) and gene co-expression networks.
RESULTS: High WNT7A expression was identified as a significant predictor of poor Overall Survival (OS) in the TCGA cohort (P < 0.05) and validated in the external cohort (P < 0.05). Multivariate analysis confirmed WNT7A as an independent prognostic risk factor (HR = 1.085, P = 0.036). Immunologically, WNT7A expression was positively correlated with MDSC infiltration (R = 0.43, P < 0.001), suggesting a shift towards an immune-tolerant phenotype. Mechanistically, GSEA revealed a robust activation of inflammatory signaling in the high-WNT7A group. Specifically, the TNFA Signaling via NF-κB pathway was significantly enriched(NES = 2.52, P < 0.001). Consistent with this pathway activation, WNT7A showed a statistically significant positive correlation with CCL2 (P < 0.001), a critical chemokine for MDSC recruitment, implicating the NF-κB/CCL2 axis in this process.
CONCLUSION: WNT7A serves as a prognostic biomarker linked to immune evasion in LUAD, potentially by modulating the NF-κB/CCL2/MDSC axis. This study identifies WNT7A as a potential therapeutic target to remodel the immune microenvironment, providing a rationale for future investigations into WNT-targeted strategies to improve immunotherapy efficacy.
PMID:41946008 | DOI:10.1016/j.cyto.2026.157144